Irazu Oncology is a biotechnology company focused on developing advanced cancer vaccines using their proprietary Membrane Vesicle Platform (MVP) technology. The company operates in the oncology sector, targeting a wide range of tumor types with their flexible and cost-effective vaccine platform. Irazu Oncology's core product involves the use of Outer Membrane Vesicles (OMVs) derived from engineered bacteria to present tumor antigens, which stimulate the immune system to fight cancer cells. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies looking for innovative cancer treatment solutions.

Irazu Oncology's business model revolves around research and development, clinical trials, and eventual commercialization of their vaccine platform. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their vaccines upon regulatory approval. The company leverages its strong advisory board, which includes experts from prestigious institutions like Johns Hopkins University and the University of Maryland, to guide its strategic direction and ensure scientific rigor.

Keywords: cancer vaccines, biotechnology, oncology, OMVs, tumor antigens, MVP technology, healthcare innovation, clinical outcomes, research and development, immunotherapy.